Research
Every study, decoded.
24articles on peptides, GLP-1, longevity science, and biohacking. We read the trial data so you don't have to.
Longevity
Why Everyone in Longevity Is Suddenly Stacking NAD+ With Peptides
NAD+ levels drop 50% by age 60. Longevity docs are restoring them with NMN and stacking targeted peptides in phased protocols, here's the science behind what actually works.
3 May 2026
Longevity
GLP-1 Drugs Aren't Just For Weight Loss Anymore, They're Becoming Longevity Medicine
GLP-1 drugs reduce cardiac events and protect kidneys even without major weight loss. Researchers are reconsidering them as longevity medicine.
3 May 2026
Longevity
FOXO4-DRI Hasn’t Hit Human Trials Yet, Here’s Why Longevity People Still Talk About It
FOXO4-DRI is still stuck in animal studies, but 2026 vascular-aging data and fresh senolytic trials explain why it keeps trending. Here’s the realistic state of play.
3 May 2026
Longevity
Why NAD+ Testing is Trending in 2026 (And Why Injectable NR Might Be the Next Move)
NAD+ drops 50% by age 50. Injectable NR and NMNH are changing the game. Here's why oral supplements often fail, and what the 2026 research shows.
3 May 2026